Clinical Trial Update: Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC) [Phase 3]

View source ↗

Summary

A Phase 3 study (LIBERTY-CPUO-CHIC) is evaluating the efficacy and safety of subcutaneous dupilumab for chronic pruritus of unknown origin in adults. The trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus of Unknown Origin

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Sanofi | Conditions: Pruritus | Phase 3 | Status: RECRUITING